Shaanxi Meibang Pharmaceutical Group Co., Ltd.
605033.SS · SHH
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | CN¥1,642 | CN¥2,403 | CN¥2,315 | CN¥3,611 |
| - Cash | CN¥268 | CN¥481 | CN¥318 | CN¥254 |
| + Debt | CN¥72 | CN¥1 | CN¥106 | CN¥27 |
| Enterprise Value | CN¥1,446 | CN¥1,922 | CN¥2,102 | CN¥3,384 |
| Revenue | CN¥886 | CN¥699 | CN¥906 | CN¥842 |
| % Growth | 26.7% | -22.8% | 7.5% | – |
| Gross Profit | CN¥253 | CN¥221 | CN¥377 | CN¥322 |
| % Margin | 28.5% | 31.6% | 41.6% | 38.3% |
| EBITDA | CN¥60 | CN¥84 | CN¥169 | CN¥155 |
| % Margin | 6.7% | 12% | 18.6% | 18.4% |
| Net Income | CN¥37 | CN¥58 | CN¥145 | CN¥126 |
| % Margin | 4.2% | 8.2% | 16% | 14.9% |
| EPS Diluted | 0.27 | 0.43 | 1.07 | 1.14 |
| % Growth | -37.2% | -59.8% | -6.1% | – |
| Operating Cash Flow | CN¥280 | CN¥335 | CN¥126 | -CN¥109 |
| Capital Expenditures | -CN¥159 | -CN¥204 | -CN¥109 | -CN¥107 |
| Free Cash Flow | CN¥122 | CN¥131 | CN¥17 | -CN¥215 |